Topic resource collection
Approved comparison material connected to this topic.
6 resourcesRead both sides
BPC-157 NMDA modulation, VEGF upregulation, substance P reduction Neuropathic (post-herpetic neuralgia, diabetic neuropathy, CIPN) Intranasal 250–500mcg daily OR subcutaneous 250–500mcg twice daily Phase II trials. Moderate evide…
BPC-157 VEGF upregulation, angiogenesis promotion, collagen synthesis acceleration Preclinical + case series (no RCTs in humans for spinal applications) 250–500mcg subcutaneously daily for 8–12 weeks Acute disc herniation, annula…
The peptide market expanded rapidly in 2025–2026, and with it came exaggerated claims. BPC-157 has human trial data for tendon healing and gastric ulcer repair. It does not have Phase 3 human data specifically for osteoarthritis …
Pre-2025 Monotherapy BPC-157 (250–500 mcg) Daily or every other day 8–12 weeks 18–22% vs baseline 25–30% improvement Outdated. Fails to leverage TB-500 synergy and misses VEGF stabilization window 2026 Combination Standard BPC-15…
Before diving into scenario-based applications, here's how the primary joint pain peptides compare across mechanism, dosing, evidence grade, and practical use cases. BPC-157 COL2A1 upregulation, mTOR-independent collagen synthesi…
BPC-157 VEGF upregulation, FAK-paxillin pathway activation. Promotes angiogenesis and collagen synthesis 250–500 mcg daily, subcutaneous or intramuscular 2–4 weeks for tendon/ligament symptoms Acute tendinopathy, ligament sprains…